Skip to main content

Table 2 Patient’s clinical characteristics

From: Improving quality of care and clinical outcomes for rectal cancer through clinical audits in a multicentre cancer care organisation

 

Total patients

Centre A

Centre B

Centre C

ACOR-1

(N = 120)

ACOR-2

(N = 120)

p-value

ACOR-1

(N = 40)

ACOR-2

(N = 40)

p-value

ACOR-1

(N = 40)

ACOR-2

(N = 40)

p-value

ACOR-1

(N = 40)

ACOR-2

(N = 40)

p-value

Sex

 Men

86 (71.7%)

85 (70.8%)

>  0.99

29 (72.5%)

25 (62.5%)

0.47

27 (67.5%)

32 (80%)

0.31

30 (75%)

28 (70%)

0.80

 Women

34 (28.3%)

35 (29.2%)

11 (27.5%)

15 (37.5%)

13 (32.5%)

8 (20%)

10 (25%)

12 (30%)

Age (years)

  < 60

28 (23.3%)

42 (35%)

0.13

13 (32.5%)

12 (30%)

0.59

9 (22.5%)

15 (37.5%)

0.45

6 (15%)

15 (37.5%)

0.15

 60–69

42 (35%)

37 (30.8%)

11 (27.5%)

13 (32.5%)

16 (40%)

12 (30%)

15 (37.5%)

12 (30%)

 70–79

40 (33.3%)

28 (23.3%)

13 (32.5%)

9 (22.5%)

13 (32.5%)

10 (25%)

14 (35%)

9 (22.5%)

  ≥ 80

10 (8.3%)

13 (10.8%)

3 (7.5%)

6 (15%)

2 (5%)

3 (7.5%)

5 (12.5%)

4 (10%)

Histology

 Invasive adenocarcinoma

119 (99.2%)

120 (100%)

>  0.99

40 (100%)

40 (100%)

>  0.99

40 (100%)

40 (100%)

>  0.99

39 (97.5%)

40 (100%)

>  0.99

 Squamous cell carcinoma

1 (0.8%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (2.5%)

0 (0%)

Histological grade

 Well differentiated

43 (35.8%)

51 (42.5%)

0.37

9 (22.5%)

3 (7.5%)

0.01†

17 (42.5%)

18 (45%)

0.60

17 (42.5%)

30 (75%)

0.015†

 Moderately differentiated

20 (16.7%)

25 (20.8%)

3 (7.5%)

14 (35%)

7 (17.5%)

9 (22.5%)

10 (25%)

2 (5%)

 Poorly differentiated

4 (3.3%)

2 (1.7%)

1 (2.5%)

0 (0%)

0 (0%)

1 (2.5%)

3 (7.5%)

1 (2.5%)

NR

53 (44.2%)

42 (35%)

27 (67.5%)

23 (57.5%)

16 (40%)

12 (30%)

10 (25%)

7 (17.5%)

Distance from tumour to mesorectal fascia

  ≤ 1 mm

29 (24.2%)

43 (35.8%)

0.001‡

9 (22.5%)

13 (32.5%)

0.24

14 (35%)

14 (35%)

0.07

6 (15%)

16 (40%)

0.01†

  > 1 mm

45 (37.5%)

56 (46.7%)

14 (35%)

17 (42.5%)

19 (47.5%)

25 (62.5%)

12 (30%)

14 (35%)

 Not reported

46 (38.3%)

21 (17.5%)

17 (42.5%)

10 (25%)

7 (17.5%)

1 (2.5%)

22 (55%)

10 (25%)

Distance from tumour to anal verge

 0–5 cm

24 (29.3%)

37 (35.9%)

0.51

2 (22.2%)

8 (32%)

0.15

13 (33.3%)

13 (33.3%)

> 0.99

9 (26.5%)

16 (41%)

0.42

  > 5–10 cm

41 (50%)

43 (41.7%)

7 (77.8%)

11 (44%)

15 (38.5%)

15 (38.5%)

19 (55.9%)

17 (43.6%)

  > 10 cm

17 (20.7%)

23 (22.3%)

0 (0%)

6 (24%)

11 (28.2%)

11 (28.2%)

6 (17.6%)

6 (15.4%)

Stage

 I

2 (1.7%)

0 (0%)

0.38

0 (0%)

0 (0%)

0.95

1 (2.5%)

0 (0%)

0.384

1 (2.5%)

0 (0%)

0.679

 II

14 (11.7%)

10 (8.3%)

7 (17.5%)

6 (15%)

4 (10%)

1 (2.5%)

3 (7.5%)

3 (7.5%)

 III

94 (78.3%)

97 (80.8%)

30 (75%)

31 (77.5%)

31 (77.5%)

34 (85%)

33 (82.5%)

32 (80%)

 IV

10 (8.3%)

13 (10.8%)

3 (7.5%)

3 (7.5%)

4 (10%)

5 (12.5%)

3 (7.5%)

5 (12.5%)

  1. ACOR clinical audit for radiation oncology, ICS Institut Català de la Salut, ICO Institut Català d’Oncologia, NR not reported
  2. *p-value 0.05 to 0.01; †p-value ≤0.01; ‡p-value ≤0.001